The Retina Center of St. Louis County Applauds Data Confirming Dietary Oral Zeaxanthin Decreases the Progression of Wet Age-Related Macular Degeneration
The study confirmed both an earlier comparative trial and two-year randomized clinical trial that 20 mg of dietary zeaxanthin daily decreases the chances of developing neovascular (wet) age-related macular degeneration in the second eye.
- The study confirmed both an earlier comparative trial and two-year randomized clinical trial that 20 mg of dietary zeaxanthin daily decreases the chances of developing neovascular (wet) age-related macular degeneration in the second eye.
- The five-year follow -up, case-control study revealed that oral zeaxanthin decreases the incidence of wet macular degeneration in the second eye by 54% in those who already have wet macular degeneration in the first eye.
- “These results are really remarkable,” said Joseph Olk, MD, lead practitioner at The Retina Center of St Louis County and co-author of the study.
- The Retina Center of St. Louis County Is an approved AMD Center of Excellence and we strive to provide the highest level of patient care and personal attention.